Ghorbanihaghjo Amir, Argani Hassan, Rahbaninoubar Mohammad, Rashtchizadeh Nadereh
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz- Iran.
Clin Biochem. 2005 Dec;38(12):1076-80. doi: 10.1016/j.clinbiochem.2005.08.006. Epub 2005 Sep 8.
This study was designed to determine the effect of nandrolone decanonate (ND) on HDL-C, apolipoproteins and paraoxonase (PON) activity in stable hemodialysis patients.
64 hemodialysis patients were treated with ND at a dose of 100 mg/I.M./week for 4 months. HDL-C, Apo-AI, Apo B, concentrations and PON activity were measured before and after 2 and 4 months of treatment as well as 2 months after withdrawing the treatment.
After 4 months of treatment, an elevation in the serum levels of Apo B (P<0.0001) and a marked decrease in the concentration of HDL-C (P<0.0001), Apo-AI (P<0.0001) and PON activity (P<0.0001) were found. A significant correlation between PON and both Apo-AI (r=0.270, P<0.04) and HDL-C (r=0.455, P<0.0001) and also between HDL-C and Apo-AI (r=0.305, P<0.02) were found.
Results revealed the adverse effects of ND on apolipoprotein levels in our study population. It is possible that ND reduces PON activity mostly by reducing both the HDL-C and Apo-AI levels.
本研究旨在确定癸酸诺龙(ND)对稳定期血液透析患者高密度脂蛋白胆固醇(HDL-C)、载脂蛋白和对氧磷酶(PON)活性的影响。
64例血液透析患者接受每周100mg肌内注射剂量的ND治疗,为期4个月。在治疗2个月和4个月后以及停药2个月后测量HDL-C、载脂蛋白A-I(Apo-AI)、载脂蛋白B(Apo B)浓度和PON活性。
治疗4个月后,发现血清Apo B水平升高(P<0.0001),HDL-C浓度(P<0.0001)、Apo-AI(P<0.0001)和PON活性显著降低(P<0.0001)。发现PON与Apo-AI(r=0.270,P<0.04)和HDL-C(r=0.455,P<0.0001)之间以及HDL-C与Apo-AI(r=0.305,P<0.02)之间存在显著相关性。
结果揭示了ND对我们研究人群载脂蛋白水平的不良影响。ND可能主要通过降低HDL-C和Apo-AI水平来降低PON活性。